Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Guideline-directed medical therapy and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: analysis of two nationwide retrospective cohort studies

Jin Z, Aa G, Guo Y, Liu H, Sun H, Li Z, Ma M, Fonarow G, Gao Y, Zhao D, Yang Q, Zhou X; CCC-AF[...]

Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections, Recesses, and Sinuses

Miyazaki Y, Rimmer M, Peacock WJ, Xu S, Shivkumar K, Mori S. Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections,[...]